Search Bar & Filters
Found 16 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
This study evaluates the immediate and long-term effects of structured breathing exercises on mental health symptoms such as anxiety, depression, perceived stress, and sleep quality in healthcare professionals. The research aims to understand how breathing practices might support mental well-being and resilience in this population. Participants will engage in self-guided structured breathing sessions lasting 15, 30, or 36 minutes, tailored to their personal skill level. These sessions are designed to improve brain circulation and mental well-being. The study uses a single group design without a comparison group, focusing on this breathing intervention over a four-month period. Throughout the study, participants will use a mobile app to track adherence, engagement, and satisfaction with the breathing exercises. Researchers will assess feasibility through recruitment ease, retention rates, and intervention acceptability. Mental health outcomes and participant feedback will be collected at regular intervals during the four months of study participation.
Actively Recruiting
Researchers are studying the quality of life effects in men with localized prostate cancer undergoing two different types of radiation therapy. The trial compares near margin-less adaptive radiation therapy ART, which adapts treatments based on ongoing imaging, to the standard stereotactic ablative body radiotherapy SABR given in five sessions. This study aims to see if the shorter ART treatment with smaller radiation margins can reduce side effects and maintain effectiveness compared to standard SABR. Participants are randomly assigned to one of two groups. One group receives near margin-less ART in two treatment sessions spaced at least three days apart, with imaging such as cone beam CT, CT, or MRI to guide therapy. The other group undergoes standard SABR in five sessions spaced at least two days apart, also with CT or MRI scans. Following treatment, patients are monitored regularly with follow-up visits at 1, 3, and 6 months, then every six months for up to five years. Throughout the study, participants complete questionnaires on quality of life, urinary and bowel symptoms, erectile function, and financial impact. Doctors track side effects using standard criteria and monitor cancer outcomes including biochemical recurrence and survival over five years. Imaging and treatment details are recorded to explore relationships with outcomes. This comprehensive monitoring helps assess the benefits and risks of the two radiation approaches over time.
Actively Recruiting
Researchers are studying adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancers who are starting systemic cancer treatments such as chemotherapy or immune checkpoint inhibitors. The purpose is to understand how cannabis and cannabinoid use relates to cancer-related symptoms over one year. This observational study enrolls 2000 participants to explore these associations in community oncology settings. Participants do not receive any experimental treatments but complete surveys and have their medical records reviewed. Assessments occur monthly for up to 12 months, capturing cannabis use, perceived benefits and harms, and adverse effects alongside symptom tracking. There is an optional sub-study for some participants receiving immune checkpoint inhibitors at specific cancer centers. During the study, participants complete monthly surveys either online at home, in clinic, or other locations, and their medical records are reviewed for treatment and symptom information. Researchers measure cancer-related symptoms and cannabis use patterns over time. The study monitors participants for up to one year to evaluate symptom changes and cannabis-related effects, with no intervention administered by the study team.
Actively Recruiting
Healthy Volunteer
Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.
Actively Recruiting
Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.
Actively Recruiting
This research aims to evaluate the feasibility of a structured breathing intervention called Seokmun Hoheup in adolescents aged 12 to 17 years diagnosed with mild to moderate anxiety andor depression. The study focuses on both rural and non-rural adolescents who receive care at outpatient pediatric and childadolescent psychiatry clinics. The purpose is to understand how this breathing practice might support mental health in this group. Participants will follow the structured breathing program at least three times per week. The practice begins with 15-minute sessions and gradually increases to 30 and then 36 minutes over the course of the program. This intervention is behavioral and is designed to be performed regularly by the adolescent patients throughout the study. During the study, researchers will assess feasibility, acceptability, and appropriateness of the breathing intervention after four months using standardized measures. They will also monitor recruitment and retention rates, system usability, total log-ins, and completion rates of assigned breathing sessions. Participants will be involved over four months, with evaluations based on their engagement and feedback regarding the breathing practice.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a new artificial intelligence AI algorithm designed to automatically outline normal structures in computed tomography CT scans used for radiation therapy planning. This observational study aims to measure how useful this AI tool is by collecting feedback on its performance and function from clinical staff involved in segmentation tasks. Participants in the study will not receive any treatment but will complete surveys to provide their observations about the AI algorithms accuracy and usability in normal tissue segmentation. The study involves clinical staff employed at Mayo Clinic locations who participate in normal tissue segmentation as part of their routine work. During the study, participants will complete surveys regarding the AI algorithms functionality and effectiveness in segmenting normal structures. The main measure is the proportion of success based on baseline observations. The study is expected to continue until November 2027 and includes healthy volunteers. Participants feedback will help assess the AI tools practical utility in radiation treatment planning.
Actively Recruiting
Researchers are evaluating golcadomide and rituximab as bridging treatments before chimeric antigen receptor CAR T-cell therapy in patients with aggressive B-cell non-Hodgkin lymphoma that has relapsed or did not respond to previous treatments. This phase II trial aims to improve the chances of patients qualifying for CAR T-cell therapy, which offers a potential for cure but is not accessible to many due to disease relapse or progression. Participants eligible for CAR T-cell therapy receive golcadomide orally once daily on days 1 to 14 of each 28-day cycle, and rituximab intravenously on days 1, 8, 15, and 22 during the first cycle, then on day 1 of subsequent cycles. After one cycle, they undergo leukapheresis followed by an additional cycle of the combination as bridging therapy before standard CAR-T treatment. Patients not initially eligible receive up to 12 cycles of golcadomide and rituximab with adjusted schedules and may later become eligible for CAR-T therapy. Optional bridging therapy cycles may also be given based on physician choice. During the study, participants undergo blood sample collection, PETCT or CT scans, and possibly bone marrow biopsies as needed. CAR-T eligible patients are followed up at 30, 90, and 180 days post-CAR-T therapy, then every six months for up to two years. CAR-T ineligible patients have follow-ups starting 28 days after treatment and then every three months for one year until disease progression or other treatments begin. Researchers assess disease control rates, response rates, safety, progression-free survival, and overall survival throughout the study period.
Actively Recruiting
Researchers are evaluating whether high-dose gabapentin can reduce the need for opioid pain medications in patients undergoing chemotherapy and radiation for squamous cell carcinoma of the head and neck. Oral mucositis, a painful side effect of radiation, often requires opioid treatment which can cause many side effects and long-term use concerns. This phase III trial aims to see if gabapentin can better manage mucositis pain compared to placebo. Participants are randomly assigned to receive either gabapentin or a placebo starting at the eighth radiation treatment. Both groups receive standard chemotherapy, radiation, and pain care. Gabapentin or placebo is given orally once daily on day 1, twice daily on day 2, and three times daily from day 3 onward. Treatment continues until mucositis symptoms improve and other pain medications stop, followed by a gradual dose reduction over 11 days. Blood samples are collected throughout. During the study, participants opioid use, pain levels, and quality of life are regularly assessed. Follow-up visits occur at 4 weeks, 3 months, and 6 months after chemoradiation ends. Researchers monitor pain scores, opioid use duration, adverse effects, feeding tube needs, and other health measures to understand gabapentins impact on pain and treatment outcomes.
Actively Recruiting
Researchers are studying patients with high-risk smoldering multiple myeloma to compare how well lenalidomide and dexamethasone work with or without daratumumab in treating this condition. The trial aims to assess overall survival, progression-free survival, response rates, safety, and quality of life among participants, while also exploring treatment adherence and disease markers over time. Participants are randomly assigned to one of two groups. One group receives daratumumab intravenously on a set schedule along with oral lenalidomide daily and oral dexamethasone on specified days in 28-day treatment cycles for up to 24 courses. The other group receives only oral lenalidomide and dexamethasone on a similar 28-day cycle schedule for the same duration, unless disease progression or unacceptable side effects occur. Throughout the study, participants will undergo regular assessments including blood tests, bone marrow biopsies, imaging scans, and questionnaires to monitor disease status, treatment effects, and quality of life. Follow-up visits will continue every 3 to 12 months for up to 15 years after study treatment ends to track long-term outcomes. Researchers will measure survival, symptom changes, adverse events, and minimal residual disease levels to evaluate treatment impact.
1-10 of 16
1